IGM Biosciences Announces Second Quarter 2022 Financial
– Continued Advancement in Clinical Development of Imvotamab (IGM-2323) and IGM-8444 – – Received $150 Million Upfront Payment in Connection with Closing...
Source: globenewswire.com
Page 6 - Fred Schwarzer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Fred Schwarzer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Fred Schwarzer Today - Breaking & Trending Today
Sanofi and IGM Biosciences team up to develop antibody agonists
Collaboration will involve the development of new class IgM antibodies with a view to gaining market approval - News - PharmaTimes
Source: pharmatimes.com
Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
Sanofi (NASDAQ: SNY) and IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies ...
Source: pharmiweb.com
IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
IGM Biosciences Announces Leadership Appointments and
– John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious...
Source: globenewswire.com